Jump to content
SCLERO.ORG
Sclero Forums

Search the Community

Showing results for tags 'immunosuppressants'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Worldwide
    • Welcome: Guidelines and FAQs
    • Sclero Forums (MAIN)
    • UK Scleroderma
    • News
    • Personal Support

Blogs

  • CFM Babs from Chorley FM
  • barefut impressions
  • My Two Cents...
  • Amanda Thorpe's Blog
  • Joelf's Blog
  • Michael Thorpe's Blog

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


Location

Found 14 results

  1. Does an Autoimmune Disorder Affect My Covid-19 Risks? Patients with conditions like lupus and rheumatoid arthritis, who may take immune suppressing drugs, do not appear to be at greatly increased risk from coronavirus. New York Times, 11/18/2020. (Also see Immunosuppressants) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  2. Lenabasum Fails to Show Efficacy in Diffuse Cutaneous Scleroderma (dcSSc), Phase 3 Trial Shows. Treatment with lenabasum failed to outperform a placebo when given as an add-on to standard immunosuppressants in adults with dcSSc, top-line data from a Phase 3 trial show. Scleroderma News, 09/09/2020. (Also see Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  3. Rituximab (RTX) as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease (SSc-ILD) unresponsive to conventional immunosuppression. Based on our results, RTX's use as an add-on treatment to MMF appears to be effective as a rescue therapy in patients with a more aggressive SSc-ILD phenotype. Seminars in Arthritis and Rheumatism, 08/08/2020. (Also see Cellcept and Biologic Agents) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and othe
  4. Comparative Persistence of Methotrexate (MTX) and Tumor Necrosis Factor Inhibitors (TNFi) in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. Concomitant use of MTX with a TNFi, however, is associated with improved TNFi persistence in all 3 diseases. PubMed, J Rheumatol, 2020 Jun 1;47(6):826-834. (Also see Treatments for Rheumatoid Arthritis, Psoriasis and Psoriatic Arthritis, Ankylosing Spondylitis and Immunosuppressants) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles
  5. The Systemic Sclerosis Patient in the COVID-19 Era: The Challenging Crossroad Between Immunosuppression, Differential Diagnosis and Long-Term Psychological Distress. The rheumatologist in daily clinical practice should carefully differentiate the possible COVID-19 infection in order to optimize the patient management. PubMed, Clin Rheumatol, 2020 Jun 8;1-5. (Also see Correlation between Pulmonary Fibrosis and other Diseases or Complications) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  6. Systemic Sclerosis and Vaccinations. Age over 65 years old, interstitial lung disease, and ongoing immunosuppressive therapy were significantly related with acceptance to both vaccinations using univariate analyses. PubMed, Vaccines (Basel), 2020 Apr 28;8(2). (Also see Vaccinations) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  7. Type 2 Polarized T Cell Phenotype is Associated with Methotrexate (MTX) Non-response in Patients with Rheumatoid Arthritis (RA). MTX-non-responsive RA patients exhibit a bias towards type 2-polarized T cell inflammatory responses. PubMed, Arthritis Rheumatol, 02/10/2020. (Also see Diagnosis of Rheumatoid Arthritis, Immunosuppressants and B Cells and T Cells) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  8. Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis (SSc): A Retrospective Analysis of a US Healthcare Claims Population. One-third of patients with SSc in the healthcare claims population received immunomodulating therapy during the first year after diagnosis. PubMed, Rheumatol Ther, 11/16/2019. (Also see Immunosuppressants) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  9. Cytometric Characterization of Main Immunocompetent Cells in Patients with Systemic Sclerosis (SSc): Relationship with Disease Activity and Type of Immunosuppressive Treatment. In SSc patients, increment of T double positive and reduction of T double negative as well as natural killer and natural killer T cells were observed. PubMed, J Clin Med, 2019 May 8;8(5). (Also see Natural Killer Cells) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  10. Scientists Are Teaching the Body to Accept New Organs. Patients receiving new kidneys and livers must take damaging anti–rejection drugs for the rest of their lives, but now researchers hope to train the immune system instead of just tamping it down. New York Times, 01/22/2019. (Also see Dendritic Cells and Immunosuppressants) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  11. Long–term effects of immunosuppressive therapy on lung function in scleroderma patients. Cyclophosphamide does not appear to result in clinically significant improvement of pulmonary function but fulfilled criteria of stable disease. PubMed, Clin Rheumatol, 2018 Nov;37(11):3043-3050. (Also see Immunosuppressants and Treatments for Pulmonary Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  12. Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis. Findings suggested a relationship between the addition of adalimumab at 6 months after methotrexate failure and improved outcomes. PubMed, Ann rheumatologist Dis, 08/03/2018. (Also see Treatments for Rheumatoid Arthritis and Immunosuppressants) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  13. Expression of interleukin-18 in muscle tissue of patients with polymyositis or dermatomyositis and effects of conventional immunosuppressive treatment. IL-18 is highly expressed in muscle tissue in the context of inflammatory myopathies and based on its plausible effector functions could provide a novel therapeutic target in future. PubMed, Rheumatology (Oxford), 08/08/2018. (Also see Treatments for Dermatomyositis and Polymyositis and Interleukins) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related art
  14. Comparing ultraviolet light A photo(chemo)therapy with Methotrexate (MTX) protocol in childhood localized scleroderma: Evidence from systematic review and meta–analysis approach. Our study supports the combination of MTX and glucocorticoids in patients with a high risk of complication and UVA1 could represent a therapeutic option in patients with limited scleroderma. Seminars in Arthritis and Rheumatism, 03/30/2018. (Also see Morphea Scleroderma Treatments and Immunosuppressants) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on sc
×
×
  • Create New...